Trabectedin for advanced soft tissue sarcomas: optimizing use

References

• LeahyMGarcia Del MuroXReichardtPChemotherapy treatment patterns and clinical outcomes in patients with metastatic soft tissue sarcoma. The SArcoma treatment and Burden of Illness in North America and Europe (SABINE) studyAnn Oncol201223102763277022492696
   PubMed Web of Science ®Google Scholar
• Van GlabbekeMvan OosteromATOosterhuisJWPrognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens – a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group StudyJ Clin Oncol199917115015710458228
   PubMed Web of Science ®Google Scholar
• van OosteromATMouridsenHTNielsenOSEORTC Soft Tissue and Bone Sarcoma GroupResults of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patientsEur J Cancer200238182397240612460784
   PubMed Web of Science ®Google Scholar
• JudsonIVerweijJGelderblomHEuropean Organisation and Treatment of Cancer Soft Tissue and Bone Sarcoma GroupDoxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trialLancet Oncol201415441542324618336
   PubMed Web of Science ®Google Scholar
• JinSGorfajnBFairclothGScottoKWEcteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activationProc Natl Acad Sci U S A200097126775677910841572
   PubMed Web of Science ®Google Scholar
• MinuzzoMMarchiniSBrogginiMFairclothGD’IncalciMMantovaniRInterference of transcriptional activation by the antineoplastic drug ecteinascidin-743Proc Natl Acad Sci U S A200097126780678410841573
   PubMed Web of Science ®Google Scholar
• FeuerhahnSGiraudonCMartínez-DíezMXPF-dependent DNA breaks and RNA polymerase II arrest induced by antitumor DNA interstrand crosslinking-mimetic alkaloidsChem Biol201118898899921867914
   PubMed Web of Science ®Google Scholar
• ForniCMinuzzoMVirdisETrabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumorsMol Cancer Ther20098244945719190116
   PubMed Web of Science ®Google Scholar
• Di GiandomenicoSFrapolliRBelloEMode of action of trabectedin in myxoid liposarcomasOncogene Epub20131111
   PubMed Web of Science ®Google Scholar
• Bueren-CalabuigJAGiraudonCGalmariniCMEglyJMGagoFTemperature-induced melting of double-stranded DNA in the absence and presence of covalently bonded antitumour drugs: insight from molecular dynamics simulationsNucleic Acids Res201139188248825721727089
   PubMed Web of Science ®Google Scholar
• AuneGJTakagiKSordetOVon Hippel-Lindau-coupled and transcription-coupled nucleotide excision repair-dependent degradation of RNA polymerase II in response to trabectedinClin Cancer Res200814206449645518927284
   PubMed Web of Science ®Google Scholar
• D’IncalciMBadriNGalmariniCMAllavenaPTrabectedin, a drug acting on both cancer cells and the tumour microenvironmentBr J Cancer2014111464665024755886
   PubMed Web of Science ®Google Scholar
• AtmacaHBozkurtEUzunogluSUsluRKaracaBA diverse induction of apoptosis by trabectedin in MCF-7 (HER2−/ER+) and MDA-MB-453 (HER2+/ER−) breast cancer cellsToxicol Lett2013221212813623792433
   PubMed Web of Science ®Google Scholar
• DemetriGDChawlaSPvon MehrenMEfficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedulesJ Clin Oncol200927254188419619652065
   PubMed Web of Science ®Google Scholar
• Van GlabbekeMVerweijJJudsonINielsenOSProgression-free rate as the principal end-point for phase II trials in soft-tissue sarcomasEur J Cancer200238454354911872347
   PubMed Web of Science ®Google Scholar
• Janssen Research & Development, LLCA study of trabectedin or dacarbazine for the treatment of patients with advanced liposarcoma or leiomyosarcoma Available from: http://clinicaltrials.gov/show/NCT01343277. NLM identifier: NCT01343277Accessed November 4, 2014
   Google Scholar
• BlayJYLeahyMGNguyenBBRandomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomasEur J Cancer20145061137114724512981
   PubMed Web of Science ®Google Scholar
• PautierPFloquetACupissolDLMS-02: a phase II single arm multicenter study of doxorubicin in combination with trabectedin as a first line treatment for advanced uterine leiomyosarcoma (U-LMS) and soft tissue LMS (ST-LMS): first results in patients with U-LMSJ Clin Oncol201331suppl abstr 10505
   PubMedGoogle Scholar
• GronchiABuiBNBonvalotSPhase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcomaAnn Oncol201223377177621642514
   PubMed Web of Science ®Google Scholar
• SaadaERahalCRay-CoquardIRechallenge with trabectedin in patients with locally advanced or metastatic soft tissue sarcoma following drug holiday: the experience of the French Sarcoma Group (FSG)J Clin Oncol201230suppl abstr 10062
   Google Scholar
• Le CesneABlayJYRyckewaertTResults of the prospective T-DIS randomized phase II trial comparing interruption versus continuation of trabectedin after six cycles of treatment in patients (pts) with advanced soft tissue sarcomas (ASTS)J Clin Oncol2014325s suppl abst 10523
   Google Scholar
• MecoDColomboTUbezioPEffective combination of ET-743 and doxorubicin in sarcoma: preclinical studiesCancer Chemother Pharmacol200352213113812783202
   PubMed Web of Science ®Google Scholar
• TakahashiNLiWWBanerjeeDScottoKWBertinoJRSequence-dependent enhancement of cytotoxicity produced by ecteinascidin 743 (ET-743) with doxorubicin or paclitaxel in soft tissue sarcoma cellsClin Cancer Res20017103251325711595721
   PubMed Web of Science ®Google Scholar
• BlayJYvon MehrenMSamuelsBLPhase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcomaClin Cancer Res200814206656666218927308
   PubMed Web of Science ®Google Scholar
• Martin-BrotoJLopez-PousaAGarcia del MuroXRandomised phase II trial of doxorubicin versus trabectedin plus doxorubicin in first line treatment of patients with advanced non-resectable or metastatic soft tissue sarcomas: a Spanish Group for Sarcoma Research (GEIS) studyEur Cancer Congr. (17 ECCO-38 ESMO-32 ESTRO)2013 Sep 27–Oct 1Amsterdam
   Google Scholar
  Publicado en:Eur J Cancer201349suppl 2S875 Abstr.3800
   PubMedGoogle Scholar
• Garcia-CarboneroRSupkoJGManolaJPhase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapyJ Clin Oncol20042281480149015084621
   PubMed Web of Science ®Google Scholar
• Le CesneABlayJYJudsonIPhase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trialJ Clin Oncol200523357658415659504
   PubMed Web of Science ®Google Scholar
• Garcia-CarboneroRSupkoJGMakiRGEcteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic studyJ Clin Oncol200523245484549216110008
   PubMed Web of Science ®Google Scholar
• GrossoFJonesRLDemetriGDEfficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective studyLancet Oncol20078759560217586092
   PubMed Web of Science ®Google Scholar
• D’IncalciMGalmariniCMA review of trabectedin (ET-743): a unique mechanism of actionMol Cancer Ther2010982157216320647340
   PubMed Web of Science ®Google Scholar
• ChoiHCharnsangavejCFariaSCCorrelation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteriaJ Clin Oncol200725131753175917470865
   PubMed Web of Science ®Google Scholar
• PenelNDemetriGDBlayJYGrowth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapyAnn Oncol201324253754223117071
   PubMed Web of Science ®Google Scholar
• YovineARiofrioMBlayJYPhase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patientsJ Clin Oncol200422589089914990645
   PubMed Web of Science ®Google Scholar
• Le CesneAYovineABlayJYA retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trialsInvest New Drugs20123031193120221484250
   PubMed Web of Science ®Google Scholar
• Paz-AresLLópez-PousaAPovedaATrabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasoneInvest New Drugs201230272974020960029
   PubMed Web of Science ®Google Scholar
• GrossoFDileoPSanfilippoRSteroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcomaEur J Cancer200642101484149016737808
   PubMed Web of Science ®Google Scholar
• DonaldSVerschoyleRDGreavesPComplete protection by high-dose dexamethasone against the hepatotoxicity of the novel antitumor drug yondelis (ET-743) in the ratCancer Res200363185902590814522916
   PubMed Web of Science ®Google Scholar
• GrossoFD’IncalciMCartoafaMA comprehensive safety analysis confirms rhabdomyolysis as an uncommon adverse reaction in patients treated with trabectedinCancer Chemother Pharmacol20126961557156522484722
   PubMed Web of Science ®Google Scholar
• CesneALJudsonIMakiRTrabectedin is a feasible treatment for soft tissue sarcoma patients regardless of patient age: a retrospective pooled analysis of five phase II trialsBr J Cancer201310971717172424022187
   PubMed Web of Science ®Google Scholar